Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celltrion Hit By Truxima Price Cut, Temporary Utilization Rate Drop

Executive Summary

Intensifying competition in the global biosimilars space and a temporary drop in its factory utilization rate took a toll on Celltrion's earnings in the third quarter, but analysts still expect a rosy outlook next year amid the expected US launches of biosimilar rituximab and trastuzumab, and the first subcutaneous version of Remsima on the horizon in Europe.

You may also be interested in...

Korea 2018 Review: Hopes And Worries Coexist In Pharma Sector

As the year end approaches, Scrip wraps up what major events made headlines in the South Korean pharma/biotech sector in 2018.

Celltrion’s Global Ambitions On Track As Third Biosimilar Approved In US

With the US approval of its third biosimilar product, Herzuma, Korean group Celltrion appears to be on a continued growth track in the global market, despite intensifying competition. The company is counting on Herzuma’s potential to rapidly replace Herceptin in the world’s biggest pharma market, given the higher price of the original drug.

Novartis Gives Up On Rituxan Biosimilar For US Market

Thwarted by the FDA, Novartis sees better opportunities for other biosimilars in its portfolio and has decided not to pursue a refiling for its version of Roche's blockbuster Rituxan. However CEO Vas Narasimhan told Scrip that the US remains very much a focus of the group's biosimilars strategy.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts